Platelet monoamine oxidase B activity in Parkinson's disease: A re-evaluation

1993 ◽  
Vol 5 (1) ◽  
pp. 1-4 ◽  
Author(s):  
J. Jarman ◽  
V. Glover ◽  
M. Sandler ◽  
N. Turjanski ◽  
G. Stern
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Platelet Monoamine Oxidase

Altered Platelet Monoamine Oxidase-B Activity in Idiopathic Parkinson’s Disease

2009 ◽  
Vol 34 (8) ◽  
pp. 1427-1432 ◽  
Author(s):  
Maroof Husain ◽  
Rakesh Shukla ◽  
Madhu Dikshit ◽  
Pradeep K. Maheshwari ◽  
Devika Nag ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Idiopathic Parkinson’S Disease ◽  
Idiopathic Parkinson's Disease ◽  
Platelet Monoamine Oxidase

Platelet monoamine oxidase-B activity in Parkinson's disease

1989 ◽  
Vol 1 (4) ◽  
pp. 255-261 ◽  
Author(s):  
G. B. Steventon ◽  
S. G. Sturman ◽  
M. T. E. Heafield ◽  
R. H. Waring ◽  
J. Napier ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Platelet Monoamine Oxidase

scholarly journals Monoamine oxidase B inhibitors for early Parkinson's disease

2005 ◽  
Author(s):  
Kristian Turnbull ◽  
Robert Caslake ◽  
Angus Macleod ◽  
Natalie Ives ◽  
Rebecca Stowe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B ◽  
Early Parkinson’S Disease

Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease

2020 ◽  
pp. 1-9 ◽  
Author(s):  
Githa Elizabeth Mathew ◽  
Jong Min Oh ◽  
Kumar Mohan ◽  
Anandkumar Tengli ◽  
Bijo Mathew ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase B

▼ Safinamide for Parkinson’s disease

2018 ◽  
Vol 56 (5) ◽  
pp. 54-57
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Motor Fluctuations ◽  
Daily Activities ◽  
Monoamine Oxidase B ◽  
Motor Symptoms ◽  
Idiopathic Parkinson’S Disease ◽  
Mao B ◽  
Idiopathic Parkinson's Disease

▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.

Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: The degree and reversibility of human brain MAO B inhibition by Ro 19 6327

Neurology ◽  
1993 ◽  
Vol 43 (10) ◽  
pp. 1984-1984 ◽  
Author(s):  
J. S. Fowler ◽  
N. D. Volkow ◽  
J. Logan ◽  
D. J. Schlyer ◽  
R. R. MacGregor ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Human Brain ◽  
Inhibitor Therapy ◽  
Monoamine Oxidase B ◽  
Mao B

Case-Control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease

2002 ◽  
Vol 17 (6) ◽  
pp. 1305-1311 ◽  
Author(s):  
John L. Goudreau ◽  
Demetrius M. Maraganore ◽  
Matthew J. Farrer ◽  
Timothy G. Lesnick ◽  
Andrew B. Singleton ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Dopamine Transporter ◽  
Case Control Study ◽  
Case Control ◽  
Monoamine Oxidase B ◽  
Methyl Transferase ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document